Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia.
Standard
Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia. / Krausz, M; Moritz, Steffen; Lambert, Martin; Naber, Dieter.
in: INT CLIN PSYCHOPHARM, Jahrgang 15, Nr. 2, 2, 2000, S. 77-81.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia.
AU - Krausz, M
AU - Moritz, Steffen
AU - Lambert, Martin
AU - Naber, Dieter
PY - 2000
Y1 - 2000
N2 - Subjective cognitive and perceptual disturbances as assessed with the Frankfurt Complaint Questionnaire (FCQ) were correlated with chlorpromazine equivalents in 40 schizophrenic inpatients, who were treated with conventional neuroleptics. In line with previous research using 'objective' neuropsychological tests, both correlations and partial correlations (controlling for the effects of psychopathology, extrapyramidal symptoms and length of illness) confirmed that higher neuroleptic doses significantly worsen several cognitive and perceptual domains (r = 0.44 -0.54; P <or = 0.005 -0.05) with the possible exception of mnestic functions (r = 0.21 -0.24, n.s.) and language (r = 0.37 -0.38, P <0.1). The clinical importance of self-report scales for evaluating both the risks and benefits of neuroleptic treatment is discussed.
AB - Subjective cognitive and perceptual disturbances as assessed with the Frankfurt Complaint Questionnaire (FCQ) were correlated with chlorpromazine equivalents in 40 schizophrenic inpatients, who were treated with conventional neuroleptics. In line with previous research using 'objective' neuropsychological tests, both correlations and partial correlations (controlling for the effects of psychopathology, extrapyramidal symptoms and length of illness) confirmed that higher neuroleptic doses significantly worsen several cognitive and perceptual domains (r = 0.44 -0.54; P <or = 0.005 -0.05) with the possible exception of mnestic functions (r = 0.21 -0.24, n.s.) and language (r = 0.37 -0.38, P <0.1). The clinical importance of self-report scales for evaluating both the risks and benefits of neuroleptic treatment is discussed.
M3 - SCORING: Zeitschriftenaufsatz
VL - 15
SP - 77
EP - 81
JO - INT CLIN PSYCHOPHARM
JF - INT CLIN PSYCHOPHARM
SN - 0268-1315
IS - 2
M1 - 2
ER -